HPV Vaccine Recommendations and Parental Intent

Sonawane, Kalyani; Zhu, Yenan; Lin, Yueh-Yun; Damgacioğlu, Haluk; Lin, Ying; Montealegre, Jane R.; Deshmukh, Ashish A.

doi:10.1542/peds.2020-026286

Cited by 34 publications

(33 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our ad hoc analysis, less than 39% of participants who were themselves age-eligible for the HPV vaccine, or who had a family member who was age-eligible, reported discussing the vaccine with their HCP. This finding is consistent with a recent NIS study which reported that nearly one-half of HPV unvaccinated adolescents in 2018 did not receive a vaccine recommendation from their healthcare provider [ 34 ]. There are many reasons for the low prevalence of HPV vaccine discussions during HCP visits.…”

Section: Discussionsupporting

confidence: 92%

Regular Healthcare Provider Status Does Not Moderate Racial/Ethnic Differences in Human Papillomavirus (HPV) and HPV Vaccine Knowledge

et al. 2021

Self Cite

View full text Add to dashboard Cite

Background: Racial/ethnic minorities generally have a lower knowledge of human papillomavirus (HPV) and the HPV vaccine than non-Hispanic Whites. They are also less likely to have a regular healthcare provider (HCP). Given the role of HCPs in disseminating health information, we evaluated whether racial/ethnic disparities in HPV knowledge are moderated by regular HCP status. Methods: Data from the Health Information National Trends Survey Five (HINTS 5) Cycles One and Two (2017–2018) were analyzed. HPV and HPV vaccine knowledge were compared by regular HCP status across race/ethnicities. Independent partially-adjusted multivariable logistic regression models were used to assess the association between race/ethnicity and knowledge after controlling for sociodemographic characteristics. The resulting adjusted odds ratios were compared to those from fully-adjusted models that included HCP status. Results: After adjusting for regular HCP status, differences in knowledge persisted between racial/ethnic groups. Compared to Whites, Hispanics and Other race/ethnicities had significantly lower odds of having heard of HPV. Blacks, Hispanics, and Other race/ethnicities had significantly lower odds of having heard of the HPV vaccine. Conclusion: Racial/ethnic minorities had significantly lower levels of knowledge despite HCP status. These data suggest the need to address disparities in health information and strengthen provider–patient communication regarding HPV and the HPV vaccine.

show abstract

Section: Discussionsupporting

confidence: 92%

Regular Healthcare Provider Status Does Not Moderate Racial/Ethnic Differences in Human Papillomavirus (HPV) and HPV Vaccine Knowledge

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…11 , 33 Notably, over a 100% rise in safety concerns in these states was observed in recent years, leading to vaccine refusal among parents of adolescents. 34 , 35 While our findings highlight the impact of potential improvement in HPV vaccination coverage at the national level, extensive efforts will be needed in states with low HPV vaccination coverage and high vaccine hesitancy.…”

Section: Discussionmentioning

confidence: 78%

Long-term impact of HPV vaccination and COVID-19 pandemic on oropharyngeal cancer incidence and burden among men in the USA: A modeling study

Damgacioğlu

Sonawane

Chhatwal

et al. 2022

The Lancet Regional Health - Americas

Self Cite

View full text Add to dashboard Cite

Background Oropharyngeal cancer (OPC) incidence is rising rapidly among men in the United States of America (USA). We aimed to project the impact of maintaining the current HPV vaccination uptake and achieving 80% national (Healthy People) goal on OPC incidence and burden. Methods We developed an open-cohort micro-simulation model of OPC natural history among contemporary and future birth cohorts of men, accounting for sexual behaviors, population growth, aging, and herd immunity. We used data from nationally representative databases, cancer registries from all 50 states, large clinical trials, and literature. We evaluated the status quo scenario (the current HPV vaccination uptake remained stable) and alternative scenarios of improvements in uptake rates in adolescents (aged 9-17 years) and young adults (aged 18-26 years) by 2025 to achieve and maintain the 80% goal. The primary outcome was to project OPC incidence and burden from 2009 to 2100. We also assessed the impact of disruption in HPV vaccine uptake during the COVID-19 pandemic. Findings OPC incidence is projected to rise until the mid-2030s, reaching the age-standardized incidence rate of 9·8 (95% uncertainty interval [UI] 9·5-10·1) per 100 000 men, with the peak annual burden of 23 850 (UI, 23 200-24 500) cases. Under the status quo scenario, HPV vaccination could prevent 124 000 (UI, 117 000-131 000) by 2060, 400 000 (UI, 384 000-416 000) by 2080, and 792 000 (UI, 763 000-821 000) by 2100 OPC cases among men. Achievement and maintenance of 80% coverage among adolescent girls only, adolescent girls and boys, and adolescents plus young adults could prevent an additional number of 100 000 (UI, 95 000-105 000), 118 000 (UI, 113 000-123 000), and 142 000 (UI, 136 000-148 000) male OPC cases by 2100. Delayed recovery of the HPV vaccine uptake during the COVID-19 pandemic could lead to 600 (UI, 580-620) to 6200 (UI, 5940-6460) additional male OPC cases by 2100, conditional on the decline in the extent of the national HPV vaccination coverage and potential delay in rebounding. Interpretation Oropharyngeal cancer burden is projected to rise among men in the USA. Nationwide efforts to achieve the HPV vaccination goal of 80% coverage should be a public health priority. Rapid recovery of the declined HPV vaccination uptake during the COVID-19 pandemic is also crucial to prevent future excess OPC burden. Funding National Cancer Institute and National Institute on Minority Health and Health Disparities of the USA

show abstract

“…The trends in reasons for HPV vaccine hesitancy observed in this study are consistent with the literature. 21 , 22 For instance, a recent study reported that the number of clinicians recommending the HPV vaccine increased from 27.0% in 2012 to 49.3% in 2018, which might explain the decreasing trend in “Not recommended” as a reason for HPV vaccine hesitancy. 21 Similarly, a prior study reported a decline in the number of parents who did not initiate the HPV vaccine during 2010 to 2016 owing to concerns of increased sexual activity.…”

Section: Discussionmentioning

confidence: 99%

“… 21 , 22 For instance, a recent study reported that the number of clinicians recommending the HPV vaccine increased from 27.0% in 2012 to 49.3% in 2018, which might explain the decreasing trend in “Not recommended” as a reason for HPV vaccine hesitancy. 21 Similarly, a prior study reported a decline in the number of parents who did not initiate the HPV vaccine during 2010 to 2016 owing to concerns of increased sexual activity. 22 A significant increase in citing safety concerns was also reported during 2010 to 2016 in the study and this upward trend has persisted in recent years based on our analyses.…”

Section: Discussionmentioning

confidence: 99%

Trends in Human Papillomavirus Vaccine Safety Concerns and Adverse Event Reporting in the United States

et al. 2021

Self Cite

View full text Add to dashboard Cite

Key Points Question Does public sentiment of human papillomavirus (HPV) vaccine safety align with spontaneous HPV vaccine adverse event reporting data? Findings This cross-sectional analysis of the 2015 to 2018 National Immunization Survey indicates a 79.9% increase in the proportion of parents who refused the HPV vaccine for their adolescents due to safety concerns. In contrast, estimates from the national vaccine safety surveillance system found that the HPV vaccine adverse event reporting rate per 100 000 doses distributed decreased from 44.7 in 2015 to 29.4 in 2018. Meaning These findings suggest an urgent need to combat safety concerns about the HPV vaccine in the US.

show abstract

HPV Vaccine Recommendations and Parental Intent

Cited by 34 publications

References 5 publications

Regular Healthcare Provider Status Does Not Moderate Racial/Ethnic Differences in Human Papillomavirus (HPV) and HPV Vaccine Knowledge

Regular Healthcare Provider Status Does Not Moderate Racial/Ethnic Differences in Human Papillomavirus (HPV) and HPV Vaccine Knowledge

Long-term impact of HPV vaccination and COVID-19 pandemic on oropharyngeal cancer incidence and burden among men in the USA: A modeling study

Trends in Human Papillomavirus Vaccine Safety Concerns and Adverse Event Reporting in the United States

Contact Info

Product

Resources

About